Elixiron Immunotherapeutics Receives Grant From the Alzheimer’s Association to Trial Microglia-Targeting Immunotherapy

Elixiron Immunotherapeutics, a clinical stage drug development company announced that it has received a new grant from the Alzheimer’s Association Part the Cloud program to accelerate the application of EI-1071, a novel orally-administered immunomodulatory therapy for people with Alzheimer’s disease.